Effects of Valproic Acid on Proliferation, Apoptosis, Angiogenesis and Metastasis of Ovarian Cancer in Vitro and in Vivo |
Shan, Zhao
(Department of Obstetrics and Gynecology, the First Affiliated Hospital of Guangxi Medical University)
Feng-Nian, Rong (Department of Obstetrics and Gynecology, Shandong Qianfoshan Hospital) Jie, Geng (Department of Reproduction, The 174 Hospital of the PLA) Ting, Zhou (Department of Obstetrics and Gynecology, Shandong Qianfoshan Hospital) |
1 | Anderson GD (2002). Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia, Suppl 3, 53-9. |
2 | Allfrey V G, Faulkner R., Mirsky A E, (1964). Acetylation and Methylation of Histones and Their Possible Role in the Regulation of Rna Synthesis. Proc Natl Acad Sci USA, 51, 786-94. DOI |
3 | Boring C, Squires T, Tong T (1992). Cancer statistics 1992. CA Cancer J Clin, 42, 19-38. DOI ScienceOn |
4 | Bellarosa D, Bressan A, Bigioni M, et al (2012). SAHA/ Vorinostat induces the expression of the CD137 receptor/ ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line. Int J Oncol. doi: 10.3892/ijo.2012.1551. DOI |
5 | BDaud AI, Dawson J, DeConti RC, et al (2009). Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res, 7, 2479-87. |
6 | Blaheta R A., Michaelis M., Natsheh I, et al (2007). Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Cancer, 96, 1699-706. DOI |
7 | Blaheta RA, Michaelis M, Natsheh I, et al (2007). Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Cancer, 96, 1699-706. DOI |
8 | Cinatl JJ, Cinatl .J, Hernáiz Driever P, et al (1997). Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs, 8, 958-63. DOI |
9 | Chou C W, Wu M S, Huang W C, et al (2011). HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PLoS One, 3, e18087. |
10 | Chen Y, Tsai YH, Tseng SH, (2011). Combined valproic acid and celecoxib treatment induced synergistic cytotoxicity and apoptosis in neuroblastoma cells. Anticancer Res, 6, 2231-9. |
11 | Dreifuss F E, Langer D H, (1988). Side effects of valproate. Am J Med, Suppl 1A, 34-41. |
12 | Dive C, Wyllie AH (1993). Apoptosis and cancer chemotherapy. Cancer Chemotherapy, 4, 21-56. |
13 | Francisco R, Pérez-Perarnau A, Cortés C, et al (2012). Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells. Cancer Lett, 1, 42-52. |
14 | Kim M S, Blake M, Baek JH, et al (2003). Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res, 63, 7291-300. |
15 | Feng L, Pan M, Sun J, et al (2012). Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells. J Mol Med (Berl). [Epub ahead of print] |
16 | Glaser K B, (2007). HDAC inhibitors: Clinical update and mechanismbased potential. Biochem Pharmacol, 74, 659-71. DOI |
17 | Hede K, (2006). Histone deacetylase inhibitors sit at crossroads of diet, aging, cancer. J Natl Cancer Inst, 9, 377-9. |
18 | Leiva M, Moretti S, Soilihi H, et al (2012). Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. Leukemia, 7, 1630-7. |
19 | Lin CT, Lai HC, Lee HY (2008). Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci, 6, 1218-26. |
20 | Marks PA, Rifkind RA, Richon VM, et al (2001). Histone deacetylases and cancer: causes and therapies. Nature, 1, 194-202. |
21 | Morkve O, Laerum OD, (1991). Flow cytometric measurement of p53 protein expression and DNA content in paraffinembedded tissue from bronchial carcinomas. Cytometry, 5, 438-444. |
22 | Osuka S, Takano S, Watanabe S, et al (2012). Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain. Neurol Med Chir (Tokyo), 4, 186-93. |
23 | Ogryzko VV, Hira TH, Russanova VR, et al (1996). Human fibroblasts commitment to a senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent. Mol Cell Biol, 16, 5210-8. DOI |
24 | Wedel S, Hudak L, Seibel JM, et al (2011). Impact of combined HDAC and MTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clin Exp Metastasis, 5, 479-91. |
25 | Rodriguez-Menendez V, Gilardini A, Bossi M, et al (2008). Valproate protective effects on cisplatin-induced peripheral neuropathy: an in vitro and in vivo study. Anticancer Res, 1A, 335-42. |
26 | Tumber A, Collins LS, Petersen K D, et al (2007). The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol, 60, 275-83. DOI |
27 | Vallo S, Xi W, Hudak L, et al (2011). HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro. Anticancer Drugs, 10, 1002-9. |